Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 15/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309118 | 0.98 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSKKISS1R | |
| SCHEMBL25963739 | 0.91 | FOLH1 (0.46) | FOLH1CTSBCTSSCTSKKISS1R | |
| SCHEMBL30971350 | 0.91 | FOLH1 (0.51) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29335966 | 0.91 | FOLH1 (0.51) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL26222813 | 0.89 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSKOPRD1 | |
| SCHEMBL29678852 | 0.89 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSKOPRD1 | |
| SCHEMBL29008427 | 0.89 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSKOPRD1 | |
| SCHEMBL29678991 | 0.89 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSKOPRD1 | |
| SCHEMBL25963755 | 0.89 | FOLH1 (0.53) | FOLH1 | |
| SCHEMBL25963654 | 0.88 | FOLH1 (0.46) | FOLH1CTSBCTSSCTSKKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | FOLH1 2/4885CTSB 1064/4885CTSS 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.